Govrin-Yehudain Jacky, Dvir Haim, Preise Dina, Govrin-Yehudain Orel, Govreen-Segal Dael
Dr Govrin-Yehudain is President, Dr Haim is Chief Technology Officer, and Mr Govreen-Segal is Chief Executive Officer, G&G Biotechnology Ltd., Haifa, Israel. Dr Govrin-Yehudain is also Founding Plastic Surgeon, Beit Harofim Medical Center, Haifa, Israel. Dr Preise is a Senior Intern in the Department of Plant and Environmental Sciences, Weizmann Institute of Science, Rehovot, Israel. Mr Govrin-Yehudain is a Medical Student, Bar Ilan University, Ramat Gan, Israel.
Aesthet Surg J. 2015 Nov;35(8):965-71. doi: 10.1093/asj/sjv080. Epub 2015 Sep 1.
Breast augmentation and reconstruction mammaplasty have been in practice for decades and are highly prevalent surgeries performed worldwide. While overall patient satisfaction is high, common long-term effects include breast tissue atrophy, accelerated ptosis and inframammary fold breakdown. Increasing evidence attributes these events to the durative loading and compressive forces introduced by the breast implants. Mechanical challenges exceeding the elastic capacity of the breast tissue components, eventually lead to irreversible tissue stretching, directly proportional to the introduced mass. Thus, it is suggested that, contrary to long-standing dogmas, implant weight, rather than its volume, stands at the basis of future tissue compromise and deformation. A novel lightweight implant has been developed to address the drawbacks of traditional breast implants, which demonstrate equivalence between their size and weight. The B-Lite(®) breast implant (G&G Biotechnology Ltd., Haifa, Israel) design allows for a reduction in implant weight of up to 30%, while maintaining the size, form, and function of traditional breast implants. The CE-marked device can be effectively implanted using standard of care procedures and has been established safe for human use. Implantation of the B-Lite(®) breast implant is projected to significantly reduce the inherent strains imposed by standard implants, thereby conserving tissue stability and integrity over time. In summary, this novel, lightweight breast implant promises to reduce breast tissue compromise and deformation and subsequent reoperation, further improving patient safety and satisfaction.
隆乳术和乳房重建整形术已经开展了数十年，是全球范围内实施的高度普遍的手术。虽然患者总体满意度较高，但常见的长期影响包括乳腺组织萎缩、乳房下垂加速和乳房下皱襞破坏。越来越多的证据将这些情况归因于乳房植入物产生的持续负荷和压缩力。超过乳腺组织成分弹性能力的机械挑战最终会导致不可逆的组织拉伸，这与植入物的质量成正比。因此，有人提出，与长期以来的教条相反，植入物的重量而非其体积是未来组织受损和变形的根本原因。一种新型轻质植入物已被开发出来，以解决传统乳房植入物的缺点，这种新型植入物在尺寸和重量之间表现出等效性。B-Lite®乳房植入物（以色列海法市G&G生物技术有限公司）的设计可使植入物重量减轻多达30%，同时保持传统乳房植入物的尺寸、形状和功能。该获得CE标志的装置可使用标准护理程序有效植入，并且已被确定对人体使用安全。预计植入B-Lite®乳房植入物将显著降低标准植入物施加的固有应变，从而随着时间的推移保持组织稳定性和完整性。总之，这种新型轻质乳房植入物有望减少乳腺组织受损和变形以及后续再次手术，进一步提高患者安全性和满意度。
